Glaxosmithkline Pharma LT
NSE: GLAXO · Pharmaceuticals · sector
₹2,445.90NSE close 2026-10-26
Key numbers
Market cap₹41,436 cr
Price₹2,445.90
52w high / low₹3,121 / ₹2,088
P/E39.4xSector median 27.9x
P/B18.3xSector median 2.9x
Book value₹133.8
Dividend yield1.72%Sector median 0.48%
ROE50.6%Sector median 11.7%
ROCE64.1%Sector median 12.3%
OPM34.7%Sector median 14.0%
Debt / equity0.00xSector median 0.16x
EV/EBITDA28.1xSector median 18.6x
Interest cover442.9x
Current ratio2.13x
Sales growth 3y+5.5%Sector median +9.6%
Profit growth 3y+19.3%Sector median +13.3%
PEG2.66x
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹2,782 cr vs borrowings ₹0 cr (FY26): cash is higher (net cash).
- Operating profit covered interest 442.9x in the last 12 months.
- No promoter shares are pledged.
- Operating cash flow was below net profit in 4 of the last 5 years (FY26, FY24, FY23, FY22).
- Revenue was higher than a year earlier in 3 of the last 4 quarters.
- Other income was 14% of net profit in the last 12 months.
- Dividend paid in 5 of the last 5 financial years.
- Price ₹2,445.90 on 2026-10-26: -21.6% from the 52-week high, +17.1% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹3,398.40 · low ₹1,977.15
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,011 | 949 | 974 | 805 | 980 | 1,041 | 995 | 938 |
| EBITDA | 326 | 292 | 333 | 251 | 338 | 389 | 351 | 296 |
| OPM % | 32.3% | 30.7% | 34.2% | 31.2% | 34.5% | 37.4% | 35.3% | 31.5% |
| Other income | 35 | 35 | 41 | 44 | 34 | 32 | 36 | 44 |
| Net profit | 252 | 230 | 263 | 205 | 257 | 296 | 278 | 237 |
| EPS (₹) | 14.67 | 13.57 | 15.52 | 12.10 | 15.07 | 16.54 | 16.40 | 14.00 |
| Revenue YoY | -3.1% | +9.7% | +2.1% | +16.6% | ||||
| Profit YoY | +2.0% | +28.6% | +5.7% | +15.7% |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 3,278 | 3,252 | 3,454 | 3,749 | 3,822 | 3,955 |
| EBITDA | 773 | 803 | 765 | 1,182 | 1,330 | 1,374 |
| Net profit | 1,695 | 611 | 590 | 928 | 1,036 | 1,068 |
| EPS (₹) | 100.04 | 36.05 | 34.83 | 54.52 | 54.52 | 62.01 |
| Revenue growth | -0.8% | +6.2% | +8.6% | +1.9% | +5.8% | |
| Profit growth | -64.0% | -3.4% | +57.2% | +11.7% | +12.4% | |
| Dividend / share (₹) | 30.00 | 30.00 | 32.00 | 44.00 | 42.00 |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +5.5% | +3.6% | +5.8% |
| Net profit | +19.3% | +23.7% | +12.4% |
| EPS | +14.8% | +20.9% | – |
| Share price | – | -4.4% (2y) | -12.9% |
Balance sheet
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Shareholders' equity | – | 1,741 | 1,778 | 1,951 | 2,267 |
| Borrowings | – | 0 | 0 | 0 | 0 |
| Cash & equivalents | – | 1,674 | 1,876 | 2,522 | 2,782 |
| Total assets | – | 3,327 | 3,557 | 4,108 | 4,324 |
| Fixed assets | – | 295 | 297 | 270 | 274 |
| Capital work in progress | – | 20 | 14 | 14 | 33 |
| Investments | – | 0 | 0 | 0 | 0 |
| Receivables | – | 192 | 222 | 293 | 273 |
| Inventory | – | 460 | 525 | 482 | 458 |
| Payables | – | 428 | 625 | 708 | 570 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | 811 | 484 | 582 | 1,290 | 903 |
| Cash from investing | -406 | 808 | 9 | -46 | 397 |
| Cash from financing | -524 | -1,543 | -561 | -769 | -737 |
| Capex | 35 | 44 | 31 | 23 | 55 |
| Free cash flow | 776 | 440 | 551 | 1,267 | 848 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ROE % | – | 35.1% | 33.2% | 47.5% | 45.7% |
| ROCE % | – | 48.1% | 46.0% | 64.6% | 62.1% |
| Debtor days | – | 22 | 23 | 28 | 26 |
| Inventory days | – | 131 | 144 | 126 | 124 |
| Payable days | – | 122 | 171 | 186 | 154 |
| Cash conversion cycle (days) | – | 31 | -4 | -32 | -4 |
| Working capital days | – | 155 | 157 | 166 | 192 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 75.00% |
| FIIs | 4.75% |
| DIIs | 8.48% |
| of which Mutual funds | 6.07% |
| of which Insurance | 2.32% |
| Government | 0.00% |
| Public (non-institutions) | 11.77% |
| Quarter | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% |
| Promoter group | % |
|---|---|
| Glaxo Group Limited | 35.99% |
| Glaxosmithkline PTE Limited | 28.10% |
| Eskaylab Limited | 6.94% |
| Burroughs Wellcome International Limited | 3.97% |
| Public holders above 1% | % |
|---|---|
| Nippon Life India Trustee Ltd-a/c Nippon India NIF | 1.05% |
| Quant Mutual Fund-quant Elss TAX Saver Fund | 1.01% |
1,19,337 shareholders. Pledged: 0.00% of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| GLAXO | ₹41,436 cr | 39.4x | 18.3x | 50.6% | 64.1% | 34.7% | +5.5% | 1.72% |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-05-29 | Dividend | Dividend - Rs 57 Per Share |
| 2025-05-30 | Dividend | Dividend - Rs 42 Per Share |
| 2024-11-07 | Dividend | Interim Dividend - Rs 12 Per Share |
| 2024-05-31 | Dividend | Dividend - Rs 32 Per Share |
| 2023-06-30 | Dividend | Dividend - Rs 32 Per Share |
| 2022-07-07 | Dividend | Dividend - Rs 30 Per Share/Special Dividend- Rs 60 Per Share |
| 2021-07-19 | Dividend | Annual General Meeting/Dividend - Rs 30 Per Share |
| 2020-07-17 | Dividend | Dividend - Rs 20 And Special Dividend - Rs 20 Per Share |
| 2019-07-11 | Dividend | Annual General Meeting/Dividend Rs 20 Per Share |
| 2018-09-11 | Bonus | Bonus 1:1 |
| 2018-07-13 | Dividend | Dividend- Rs 35 Per Share |
| 2017-07-14 | Dividend | Dividend - Rs 30/- Per Share |
| 2016-07-15 | Dividend | Dividend Rs 50/- Per Share |
| 2015-07-23 | Dividend | Annual General Meeting/Dividend - Rs 62..50/- Per Share |
| 2014-04-03 | Dividend | Final Dividend Rs.50/- Per Share |
| 2013-04-04 | Dividend | Dividend Rs. 50 Per Share |
| 2012-03-29 | Dividend | Dividend Rs.45/- Per Share |
| 2011-03-14 | Dividend | Dividend-Rs.40/- Per Share |
| 2010-03-10 | Dividend | Dividend-Rs.30/- Pr Share |
| 2009-03-18 | Other | Div Fin-Rs.22 + Spl-Rs.18 |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY24
- Annual report FY23
- Annual report FY22
- Announcements NSE filings
- BRSR FY26
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
- Pharmaceuticals: Manufacturing, distributing, and trading in pharmaceuticals
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | GLAXO |
| BSE code | 500660 |
| ISIN | INE159A01016 |
| Face value | ₹10.0 |
| Incorporated | 1924-11-13 |
| Website | www.india-pharma.gsk.com |
| Plants (India / abroad) | 1 / 0 |
From the company's filings (BRSR FY26).
Data built 2026-10-24 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.